NascaCell will receive nonexclusive rights to aptamers for target validation, mode of action studies, drug discovery, and aptamer structure-based drug design.
Archemix and NascaCell Technologies expaned their original alliance, in which NascaCell obtained a sublicense to use Selex technology for aptamer-based target validation and drug screening applications. The new collaboration is focused on the use and development of aptamers for drug discovery applications.
Aptamers are synthetically-derived oligonucleotides. Archemix believes that they have broad application to treat a variety of human diseases.
Under the terms of the new agreement, NascaCell will receive nonexclusive rights to the use of aptamers for target validation, mode of action studies, drug discovery, and aptamer structure-based drug design. All future aptamer technology improvements will be cross-licensed between the companies. Archemix will also have the option of contracting NascaCell to generate aptamers for its own applications.
